Ban on Mailing Abortion Pills
This bill is in the early stages of the legislative process and is currently sitting with the House Committee on Energy and Commerce. Since June 23, 2026, no further action has been taken on the proposal. The committee must review the bill before it can move forward, but most bills do not receive a vote at this stage.
This bill faces strong opposition in a divided Congress and would likely be blocked by lawmakers who support abortion access.
Scores run from -100 (strongly harmful) to +100 (strongly beneficial) for each group, combining impact, certainty, scope, and duration ratings of 1-5. How impact scoring works
The bill requires an in-person visit and a doctor licensed in the patient's own state before mifepristone can be prescribed, ending the option of getting the pill through telehealth or by mail from an out-of-state provider. This mainly affects pregnant people in states with abortion bans or few providers who currently rely on mailed prescriptions, especially those who cannot easily travel or take time off work.
“Any REMS-certified provider that knowingly prescribes, dispenses, or administers mifepristone or any other abortion drug without an in-person visit with the patient for whom such drug is prescribed shall lose REMS-certified status, with respect to such drug, for a period of not less than 2 years.”
Referred to the House Committee on Energy and Commerce.
Introduced in House
The bill was officially filed and given a number. It now enters the legislative queue.
No votes, news coverage, or related bills recorded for this bill yet.
Document Type
Congressional Bill
Official Title
Ban Abortion by Mail Act
Analysis generated by AI. Always verify with official sources.